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Background: New compounds for the treatment of human African trypanosomiasis (HAT) are urgently required.
Trypanosoma brucei (T.b.) gambiense is the leading cause of HAT, yet T.b. gambiense is often not the prime target
organism in drug discovery. This may be attributed to the difficulties in handling this subspecies and the lack of an
efficient viability assay to monitor drug efficacy.
Methods: In this study, a T.b. gambiense strain, recently isolated in the D.R. Congo, was made bioluminescent by
transfection with Renilla luciferase (RLuc) without altering its in vitro and in vivo growth characteristics. A
luminescent multiplex viability assay (LMVA), based on measurement of the Renilla luciferase activity and the ATP
content of the cells within the same experiment, was investigated as an alternative to the standard fluorimetric
resazurin viability assay for drug sensitivity testing of T.b. gambiense.
Results: In a 96-well format, the RLuc transfected strain showed a detection limit of 2 × 104 cells ml-1 for the Renilla
luciferase measurement and 5 × 103 cells ml-1 for the ATP measurement. Both assays of the LMVA showed linearity
up to 106 cells ml-1 and correlated well with the cell density during exponential growth of the long slender
bloodstream forms. The LMVA was compared to the fluorimetric resazurin viability assay for drug sensitivity testing
of pentamidine, eflornithine, nifurtimox and melarsoprol with both the wild type and the RLuc transfected
population. For each drug, the IC50 value of the RLuc population was similar to that of the wild type when
determined with either the fluorimetric resazurin method or the LMVA. For eflornithine, nifurtimox and melarsoprol
we found no difference between the IC50 values in both viability assays. In contrast, the IC50 value of pentamidine
was higher when determined with the fluorimetric resazurin method than in both assays of the LMVA.
Conclusions: LMVA has some advantages for viability measurement of T.b. gambiense: it requires less incubation
time for viability detection than the fluorimetric resazurin assay and in LMVA, two sensitive and independent
viability assays are performed in the same experiment.
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Human African trypanosomiasis (HAT), or sleeping
sickness, is caused by two subspecies of Trypanosoma
brucei (T.b.) and is transmitted through tsetse flies
(Glossina spp). T.b. rhodesiense causes an acute form of
sleeping sickness in East Africa. T.b. gambiense is
responsible for the chronic form in West and Central
Africa and accounts for more than 95% of the near 10,000
sleeping sickness patients that are diagnosed and treated* Correspondence: nvanreet@itg.be
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reproduction in any medium, provided the orannually [1]. In both forms, the disease evolves from a first
stage with peripheral tissue invasion, towards a second
stage with invasion of the central nervous system. The
drugs for treating sleeping sickness are subspecies specific
due to their different metabolisation, and are disease
stage specific depending on their ability to cross the
blood–brain-barrier [2]. T.b. gambiense HAT is treated
with pentamidine (first stage) and nifurtimox-eflornithine
combination therapy or melarsoprol (second stage). T.b.
rhodesiense HAT is treated with suramin (first stage) or
melarsoprol (second stage). All these drugs are toxic and
require intramuscular or intravenous injection except foral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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new drugs for HAT aims at drugs that are safe, that
are active against both subspecies and both disease
stages, that can be given orally and that need only
one administration [4]. Whole cell in vitro high-
throughput screenings (HTS) are now in use to discover
novel trypanotoxic compounds. However, these HTS
assays are almost exclusively performed with one particu-
lar non human pathogenic strain: T. b. brucei strain 427
[5-14]. Less often a hit is confirmed in vitro and in vivo on
a collection of Trypanozoon strains, including T.b.
rhodesiense and T.b. gambiense [15-20]. To be relevant for
the current situation in the field, T.b. rhodesiense and T.b.
gambiense strains that are recently isolated from patients
with known treatment outcomes and that underwent few
in vivo and in vitro passages, should be included in these
drug discovery validation panels [21-23]. It would be even
better to include T.b. gambiense strains already in the
initial HTS screening, because, despite the high sequence
similarity between the genomes of T.b. brucei and T.b.
gambiense [24], the latter is often found to be more sus-
ceptible to drugs than other T. brucei subspecies, as
is the case for eflornithine and pentamidine [15,16,25-27].
Several factors hamper inclusion of T.b. gambiense as a
primary target organism in HTS. T.b. gambiense is par-
ticularly difficult to isolate from patients and to adapt to
mice and to in vitro culture [23,28]. Often, T.b. gambiense
leads to silent or chronic infections in mice with hardly
detectable parasites [29]. Generally, bloodstream form
parasites from in vivo or in vitro cultures are exposed to
compounds for up to 72 hours, whereafter the remaining
viability of the cells is assessed using either radio-
active, colorimetric, fluorimetric, or luminescent detec-
tion [5,9,26,30,31]. The fluorimetric resazurin viability
assay is very cost-effective, but performance is limited with
T.b. gambiense strains due to lengthy incubation times
with resazurin before detection of resorufin yields high
enough signal to background for detection. The reason for
low conversion of resazurin to resorufin is unknown, but
long term incubation times with resazurin with live or
lysed trypanosomes may affect the IC50 value of a drug
[26,31,32]. Because of their easy, sensitive and fast
readout, viability assays based on ATP detection (such
as the luminescent CellTiter-Glo assay) have been
proposed and used as an alternative viability assay for
HTS in T.b. brucei strain 427 [5,7]. Currently, there
is no reporter gene based in vitro assay employed for
HTS compound screening, either for T.b. gambiense or for
T.b. brucei and T.b. rhodesiense, unlike for other protozoan
parasites such as Plasmodium falciparum, Leishmania spp.
and Trypanosoma cruzi [33-39]. Renilla luciferase tagged
parasites have previously been generated for T.b. brucei
and T.b. gambiense and have proved effective for in vivo
parasite tracking in murine models of experimentaltrypanosomiasis [29,40] and for preclinical in vivo drug
efficacy testing [41]. Yet up to now, no in vitro application
of Renilla luciferase parasites has been described. Recently,
it has been shown that the EnduRen assay, for measure-
ment of vital in vitro Renilla luciferase activity, can be
combined with the CellTiter-Glo assay as an efficient lumi-
nescent multiplex viability assay for HTS compound
screening against Dengue [42]. Assays that measure mul-
tiple fitness parameters within the same wells, such as
multiplex assays, may decrease false-positive rates and in-
crease confidence for hit selection in HTS [43]. In the
present study, a T.b. gambiense strain that was recently iso-
lated in the Democratic Republic of the Congo was made
bioluminescent by expression of Renilla luciferase. With
this strain, the feasibility of the Enduren/CellTiter-Glo
luminescent multiplex viability assay, abbreviated as
LMVA, was compared to the fluorimetric resazurin assay
for drug sensitivity testing of the main drugs to treat T.b.




Iscove’s modified Dulbecco’s medium powder (IMDM)
and fetal calf serum (FCS; heat-inactivated; EU approved
South American origin) were purchased from Invitrogen.
Methylcellulose (5140 mPa.s) was purchased from Fluka.
All other culture media ingredients were from Sigma–
Aldrich. An HMI-9 based stock solution [44] was adapted
to prepare two culture media for use with in vitro culture
of bloodstream form T.b. gambiense [28]. Briefly, HMI-
human serum (HH) contains HMI-9 with 15% v/v FCS
and 5% v/v heat-inactivated human serum. HMI – human
serum – methylcellulose (HHM) is HH containing a final
concentration of 1.1% w/v methylcellulose. For fluorescent
and luminescent activity assays, HH was prepared from
IMDM without phenol red (Invitrogen).
T. b. gambiense MHOM/CD/INRB/2006/23A
T. b. gambiense strain MHOM/CD/INRB/2006/23A, alias
348 BT, was isolated in Mbuyi-Mayi in the Democratic
Republic of the Congo in 2006, from the blood of a second
stage patient who was cured after a 10 day melarsoprol
treatment [45]. The isolation of the bloodstream form
in vivo in rodents and the adaptation in vitro to HHM and
the confirmation of its gambiense type I genotype have
been described previously [23,28].
In vitro T.b. gambiense culture
An HHM adapted population of 348 BT, was inoculated
in 500 μl of HHM in a 48-well plate at densities between
103 – 105 cells ml-1 and maintained in logarithmic phase
growth by sub passages at appropriate dilutions after 24
to 72 hours of incubation at 37°C and 5% CO2. Cultures
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For cell counting, 20 μl were withdrawn and dispensed
in a disposable Uriglass counting chamber (Menarini).
Cultures were stepwise scaled up to 40 ml, by addition
of four volumes of fresh medium in 25 cm2 flasks once
the parasites reached a density of 5 × 105 cells ml-1. For
long term storage, cells were cryostabilised in liquid
nitrogen as tenfold concentrated log phase cultures in
90% HH with 10% glycerol.
In vivo T.b. gambiense culture
All animal experiments were approved by the Animal
Ethics Committee of the Institute of Tropical Medi-
cine Antwerp, under licence PAR019. Female OF-1
mice (40 – 50 g) (Charles River, Belgium), either im-
mune suppressed with 200 mg kg-1 cyclophosphamide
(Endoxan, Baxter) 48 h before infection or not, were
infected intraperitoneally with 2 × 105 parasites in 200 μl,
obtained from rodent blood or in vitro culture, and diluted
at least 1:1 in phosphate buffered saline + 1% glucose
pH 8.0 (PSG) [46]. The matching method was used to
monitor parasitemia in tail-blood [47] for 4 weeks after
which the animals were sacrificed.
Renilla luciferase T.b. gambiense
The pHD309 RLuc expression vector, containing RLuc
cDNA from pGL4 vector (Promega) was used for trans-
fection [40]. Parasites from flask cultures were harvested
at 5 × 105 cells ml-1 and washed twice in cytomix
(2 mM EGTA, 120 mM KCl, 0.15 mM CaCl2, 10 mM
potassium phosphate pH 7.6, 25 mM Hepes, 1 mM
hypoxanthine, 5 mM MgCl2, 5 g l
-1 glucose, 100 mg l-1
BSA). Next, they were concentrated to 5 × 107 cells ml-1
and 400 μl of this suspension was transferred into a
4 mm cuvette (BioRad), whereafter 50 μl containing
10 μg of NotI (New England Biolabs) linearised pHD309
RLuc DNA was added. Subsequently, this mixture was
pulsed once in a Gene Pulse Xcell electroporator
(BioRad; 1250 V, 25 Ω, 50 μF), transferred to 12 ml of
HH, plated in a 48-well plate in 250 μl volumes and
incubated at 37°C for 24 h. Next, 250 μl of HH
containing 2 μg ml-1 hygromycin was added. Populations
were maintained in 1 μg ml-1 hygromycin for four weeks
before cryostabilisation. The Renilla luciferase assay
system (RLAS, Promega) was used to measure the
RLuc activity from lysed cells. Forty μl of trypano-
some suspension was mixed with 10 μl of 5 x Renilla
lysis buffer and 20 μl of this solution was mixed with
100 μl of RLAS assay reagent (via dispenser) in a white
opaque 96-well plate (Perkin Elmer). Each time an aliquot
was dispensed into a well, the plate was shaken for 2 se-
conds and after a further 2 seconds delay, the number of
photons per second (CPS) was measured for 10 seconds
with a VictorX3 multimodal plate reader (Perkin Elmer).Luminescent multiplex viability assay
The luminescent multiplex viability assay (LMVA) mea-
sures first the RLuc activity in live cells with EnduRen
(Promega) and next measures the cell ATP content with
the luminescent CellTiter-Glo reagent (Promega) within
the same assay wells. Luminescence in CPS was mea-
sured with a VictorX3 multimodal plate reader (Perkin
Elmer). The EnduRen reagent was used according to the
manufacturer’s instructions (Promega). Forty-five μl of
trypanosome suspension was transferred to a half area
white opaque 96 well plate (Perkin Elmer) to which
5 μl of 60 μM EnduRen in HH (or 5 μl of HH) was
added. After 2 hours incubation at 37° C and a 10 minutes
equilibration at 25°C, the luminescence was measured by
integrating the number of photons per 1 second. Then, an
equal volume (50 μl) of reconstituted CellTiter-Glo
reagent (Promega) was added to this parasite suspension,
after 2 minutes of shaking, and a 10 minutes delay, the
number of photons per second was integrated.
LMVA performance
To assess the lower detection limit of wild type and re-
combinant trypanosome cells in HH, log phase trypano-
somes at 105 cells ml-1 were harvested, concentrated and
a tenfold dilution series was made in triplicate from 106
down to 102 cells ml-1 in 100 μl. This series was tested
with the LMVA (using a 45 μl trypanosome suspension,
as described above) and the RLAS (using 40 μl, as de-
scribed above). The luminescent values (in CPS) of the
cell containing samples were divided by the value of the
blanks without cells (signal to background) and this rela-
tive luminescence value was plotted against the number
of trypanosomes for each assay. Linear fits were used to
find the lower detection limit of the number of trypano-
some cells in each assay (at a signal to background ratio
of 3 to 1). To measure the performance of the LMVA
during the whole growth period, a trypanosome suspen-
sion of 2 × 104 cells ml-1 in 100 μl was inoculated in 15
wells and every day, for four days, triplicate wells were
sampled for cell counting (using 20 μl cell suspension, as
described above) and for the LMVA (using 45 μl cell sus-
pension, as described above). Doubling times were calcu-
lated using non-linear regression in Prism (Graphpad).
Drug sensitivity testing
Eflornithine (Sanofi Aventis) and hygromycin B (Sigma)
were prepared as 10 mg ml-1 stock solutions in distilled
water. Melarsoprol (Arsobal, Sanofi Aventis), pentami-
dine isethionate (Sanofi Aventis) and nifurtimox (Sigma)
were stored as 10 mg ml-1 stock solutions in DMSO.
A method to measure the IC50 values of compounds
in 96-well plates was performed as described else-
where [48]. Threefold drug dilutions in triplicate were
made in HH from 100 to 0.14 μg ml-1 for eflornithine
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and from 500 to 0.7 ng ml-1 for pentamidine and
melarsoprol. Each drug concentration was inoculated with
either 2 × 104 cells ml-1 or 5 × 103 cells ml-1 in a final vol-
ume of 100 μl. Next the plate was incubated for 72 hours.
For detection of hygromycin sensitivity in the fluorimetric
resazurin assay, 10 μl of 12 mg resazurin in 100 ml PBS
were added to 100 μl trypanosome suspension in a 96 well
transparent plate (Nunc). Alternatively, for comparison of
IC50 values between the LMVA and resazurin assay,
the 100 μl trypanosome suspension was split: 45 μl
were used for LMVA as described above and 45 μl
were transferred to a half area black opaque plate (Perkin
Elmer) containing 5 μl of resazurin. After 24 h at 37°C,
fluorescence was measured (excitation λ = 560 nm; emis-
sion λ = 590 nm) with a VictorX3 multimodal plate reader
using top reading (Perkin Elmer) [26]. The results were
expressed as the percent reduction in parasite viability
compared to parasite viability in control wells without
drugs, and a 50% inhibitory concentration (IC50) was cal-
culated using non-linear regression in Prism (GraphPad).
Results
In vitro adaptation in HH
To be compatible with compound screening, it was ne-
cessary to adapt the T.b. gambiense 348BT strain that
readily grows in HHM to a medium without methylcel-
lulose because the latter is very viscous, which renders
homogenous volume distribution and centrifugation very
difficult. The strain was adapted to HH medium by grad-
ually diluting out the initial 1.1% (w/v) methylcellulose
concentration in the HHM. With each daily subpassage,
1 to 5 volumes of the trypanosome suspension was
inoculated in 9 to 5 volumes of HH, making sure that
the starting cell concentration was between 5 × 104
and 1 × 105 cells ml-1. In many instances this approachFigure 1 Growth profiles of an HHM line, and from the nine subpassa
gambiense 348 BT. Vertical dotted lines mark the start of each new subpawas not successful and most subpassages resulted in
cell culture cessation. One population survived eight
subpassages in HH, whereafter its growth profile be-
came similar to the original profile in HHM. When
inoculated at ± 105 cells ml-1, the logarithmic growth
phase lasted 72 hours with a maximum population
density of ± 106 cells ml-1. This population was con-
sidered fully adapted to HH and used as such in fur-
ther experiments. Figure 1 shows the growth profiles
of the HHM adapted line, and from nine subpassages
(HH1 – HH9) that resulted in this HH adapted line.
Transfection with pHD309 RLuc
We transfected the HH adapted line of T.b. gambiense
348 BT with plasmid pHD309 RLuc and obtained 3
recombinant populations from 2 independent transfec-
tions: population #2.1, #3.1 and #3.2. Hygromycin resist-
ant populations were evident after 8 days of selection.
After 4 weeks in 1 μg ml-1 hygromycin, the IC50 value
for hygromycin, starting with a cell density of 2 × 104
cells ml-1, was calculated using the fluorimetric resazurin
assay for wild type and recombinant populations. All
recombinant populations were at least twenty times
more resistant to hygromycin than the wild type
population (Table 1).
Activity of RLuc
To select the most luminescent population, activity of the
expressed luciferase in the wild type and recombinant
populations was quantified with two assays that measure
RLuc activity either in lysed cells (RLAS, Promega) or in
live cells (EnduRen, Promega). With both RLuc activity
assays, a linear fit between the number of log phase
recombinant trypanosomes and relative luminescence
(signal to background) data was obtained until up to 106
cells ml-1, the most dense trypanosome suspension tested.ges (HH1 – HH9) that resulted in the HH adapted line of T.b.
ssage made using 90 to 50% new medium.
Table 1 Sensitivity to hygromycin and lower detection
limits of RLAS, EnduRen and CellTiter-Glo with the T.b.
gambiense 348BT wild type and three RLuc transfected
strains
Population IC 50 hygromycin
a RLASb EnduRenc CellTiter-Glod
wild type < 0.12 n.a. n.a. 218 ± 14
RLuc #2.1 7.5 ± 1.1 207 ± 22 991 ± 131 212 ± 9
RLuc #3.1 2.4 ± 0.7 810 ± 80 4804 ± 511 221 ±16
RLuc #3.2 4.2 ± 0.9 488 ± 50 3225 ± 423 215 ± 22
a reported in μg ml-1 ± SD, from 3 cultures and determined with fluorimetric
assay for measurement of reduction of resazurin.
b reported in number of cells ± SD, from 3 cultures and determined with RLAS,
a luminescent assay for detection of Renilla luciferase activity in lysed cells.
c reported in number of cells ± SD, from 3 cultures and determined with
EnduRen, a luminescent assay for detection of Renilla luciferase activity in
living cells.
d reported in number of cells ± SD, from 3 cultures and determined with
CellTiter-Glo, a luminescent assay for quantification of ATP.
n.a. = not applicable.
Figure 2 Relative luminescence of LMVA in function of cell
density tested with population RLuc # 2.1. Horizontal dotted line
represents a signal to background ratio of 3 to 1.Vertical dotted lines
mark the cell density necessary for detection at this signal to
background ratio (5 × 103 cells ml-1 for CellTiter-Glo and 2 × 104
cells ml-1 for EnduRen).
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fits was different for each of the recombinant popula-
tions and was also different between both RLuc assays
(ANOVA, p < 0.05) (Table 1). Due to its lowest detec-
tion limit in both RLuc assays, population #2.1 was
identified as the most luminescent population.
LMVA performed on cells in the logarithmic growth
phase
The CellTiter-Glo assay was used to measure the lumi-
nescence of the ATP content of wild type and recombin-
ant populations. A linear fit between the number of
trypanosomes and relative luminescence signal could be
found up to 106 cells ml-1, the most dense trypanosome
suspension tested. The lower detection limits generated
from these linear fits were equal for wild type and each
recombinant population (ANOVA, p > 0.05) (Table 1).
Importantly, the detection limit in the CellTiter-Glo
assay was not altered, whether or not the EnduRen sub-
strate was included in the medium (ANOVA, p > 0.05).
This allows the EnduRen assay to be combined with the
CellTiter-Glo assay in one multiplexed luminescent
format, i.e. the LMVA, reporting thus both on the
signal from the RLuc expression as well as on the sig-
nal of the ATP viability assay from the same wells.
Figure 2 shows that for the most luminescent popula-
tion, RLuc #2.1, we require at least ± 2 × 104 cells ml-1 to
obtain a signal to background ratio of at least 3 to 1 for
the EnduRen assay, while the CellTiter-Glo assay requires
only ± 5 × 103 cells ml-1.
LMVA performance during growth profile
The growth profiles of T.b. gambiense 348BT wild type
and RLuc #2.1 were established by the LMVA and by daily
cell counting during a 5 time-points experiment lasting
96 hours. Figure 3 shows that at a starting concentrationof 2 × 104 cells ml-1, both arms of the LMVA could record
the exponential growth of the RLuc population during the
first 72 hours. After 96 hours, when the population was in
stationary phase, the output of both luminescent assays
was lower than expected from the cell density. Doubling
times in the exponential growth phase calculated with
LMVA data, using either EnduRen or CellTiter-Glo,
did not differ significantly from the doubling time
calculated with the cell counting data nor did these
growth rates differ between wild type and RLuc #2.1
(ANOVA, p > 0.05) (Table 2).
LMVA performance in drug sensitivity screening
The IC50 values for pentamidine, eflornithine, melarsoprol
and nifurtimox were compared between the wild type and
the RLuc #2.1 populations, between one or both arms of
the LMVA and the fluorimetric resazurin viability assay
and between using 2 × 104 or 5 × 103 cells ml-1 as starting
concentration (Table 3). We could not observe a signifi-
cant difference in IC50 values between the wild type and
the RLuc population for any given viability assay
(ANOVA, p > 0.05) or starting concentration (ANOVA,
p > 0.05) when using the same drug. Furthermore, for
eflornithine, melarsoprol and nifurtimox, there was no
variation in IC50 values obtained from the different
viability assays (ANOVA, p > 0.05) when using the
same starting concentration. However, for these drugs, all
viability assays recorded significant differences in IC50
values between using 2 × 104 or 5 × 103 cells ml-1 as
a starting concentration (ANOVA, p < 0.05). In con-
trast, for pentamidine, we observed higher IC50 values
in the resazurin assay than in either the EnduRen or
CellTiter-Glo assay (ANOVA, p < 0.05) when using the
same starting concentration. However, the differences in
IC50 values between using 2 × 10
4 and 5 × 103 cells ml-1
Figure 3 Growth curve of RLuc# 2.1 in function of time, assessed by LMVA (in relative luminescence, left Y-axis) and by microscopy
(cell density, right Y-axis).
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drug (ANOVA, p > 0.05). We conclude that the presence
of pHD 309 RLuc does not influence the susceptibility of
T.b. gambiense 348 BT to any of the tested drugs, but a
particular drug may influence the IC50 value when tested
with a different viability assay (as for pentamidine), or
when a different starting concentration is used (for
eflornithine, nifurtimox and melarsoprol).
In vivo infections of wild type and recombinant 348BT
Differences in infectivity, as determined by the number
of days until the first parasite is detected (prepatent
period), and virulence, as determined by the number of
days of survival of the rodents, between the original cell
line (adapted in vivo but not in vitro), the HHM and HH
(adapted in vitro) cell lines, and the resulting RLuc cell
line, were compared by expanding each population in 4
mice treated or not with endoxan. All mice were found
parasitemic after 3 to 7 days of infection. The mean
prepatent period was not significantly different between
mice treated or not with endoxan and between the dif-
ferent trypanosome cell lines (data not shown). During
the next 3 weeks of follow up, we could sporadically de-
tect waves of parasitemia in all mice of all groups. NoTable 2 In vitro doubling time of the T.b. gambiense
348BT wild type and the recombinant RLuc #2.1 strain




wild type n.a. 12.7 ± 0.8 12.6 ± 0.9
RLuc #2.1 12.9 ± 0.7 12.4 ± 0.7 12.6 ± 0.5
a reported in h-1 ± SD, from 3 cultures.
b luminescent assay for measurement of Renilla luciferase activity in living cells.
c luminescent assay for quantification of ATP.
n.a. not applicable.mice died from the infection during the experiment and
all mice were sacrificed at day 30.
Discussion
This study was undertaken to develop a Renilla lucifer-
ase based luminescent multiplex viability assay (LMVA)
for in vitro compound screening on bloodstream form
T.b. gambiense. To obtain the RLuc transfected T.b.
gambiense, we started with a recently isolated strain that
underwent few in vivo passages in rodents and that was
adapted to in vitro HMI-9 based medium with human
serum (HH). Although nucleofection has been described
to be very efficient for transient and for stable transfection
of African trypanosomes [29,49,50], our study confirms
that transfection with pHD309 RLuc is also successful by
electroporation [40]. Due to the presence of hygromycin
phosphotransferase as resistance selection marker for
stable genomic integration of Renilla luciferase, cross
resistance against trypanotoxic hygromycin analogues may
pose a problem, as has been described for pyrimethamine
resistance of a transgenic firefly luciferase Plasmodium
strain [34]. To select the most RLuc transfected trypano-
some population, two RLuc activity assays were used. The
RLAS system is very sensitive, but is not compatible with
CellTiter-Glo and requires more manipulations than the
EnduRen assay. In the EnduRen assay, only the most
hygromycin resistant population allowed fast detection of
low numbers of cells (± 2 × 104 cells ml-1). In contrast to
the EnduRen assay, the CellTiter-Glo assay does not
require genetic manipulation of the trypanosome strain,
the assay is performed faster and has a lower detection
limit (± 5 × 103 cells ml-1). Combining the EnduRen assay
with CellTiter-Glo as two independent assays measuring
respectively the RLuc activity and the ATP content of
the cells, we were able to establish a multiplex viabi-
lity assay for which the luminescence signals correlate
well with the cell density during the proliferation of
the long slender bloodstream form trypanosomes. The
Table 3 IC50 values for eflornithine, melarsoprol, pentamidine and nifurtimox obtained with the T.b. gambiense 348BT




wild type RLuc # 2.1 wild type RLuc # 2.1 wildtype RLuc # 2.1
5 x 103 eflornithineb n.a. 1.0 ± 0.4 1.1 ± 0.4 1.0 ± 0.5 1.1 ± 0.6 1.4 ± 0.4
melarsoprolc n.a. 5.5 ± 2.1 4.5 ± 2.2 5.0 ± 1.9 6.3 ± 3.0 6.5 ± 2.3
pentamidinec n.a. 40.1 ± 11.1 43.6 ± 10.3 41.1 ± 7.5 67.5 ± 11.1 64.1 ± 13.6
nifurtimoxc n.a. 334 ± 47 274 ± 93 380 ± 84 437 ± 139 410 ± 132
2 x 104 eflornithineb n.a. 2.8 ± 0.5 3.0 ± 0.7 2.6 ± 1.0 2.6 ± 0.9 2.9 ± 0.7
melarsoprolc n.a. 11.0 ± 3.2 12.0 ± 2.8 11.5 ± 2.6 8.9 ± 2.2 11.9 ± 2.6
pentamidinec n.a. 47.5 ± 8.1 43.7 ± 10.8 48.9 ± 9.1 74.7 ± 12.3 72.5 ± 6.3
nifurtimoxc n.a. 700 ± 63 670 ± 78 720 ± 75 751 ± 174 768 ± 125
a values are the mean ± SD from 4 cultures.
b reported in μg ml-1.
c reported in ng ml-1.
d luminescent assay for measurement of Renilla luciferase activity in living cells.
e luminescent assay for quantification of ATP.
f fluorimetric assay for measurement of reduction of resazurin.
n.a. not applicable.
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the fluorimetric resazurin assay: first, viability assessment
requires less incubation time with substrate before detec-
tion takes place (2 hours vs 16 – 24 hours) and second,
two independent viability parameters are assayed in the
same experiment (RLuc activity and ATP content). Disad-
vantages of this LMVA are its higher cost compared to
the resazurin assay and the need for an RLuc transfected
trypanosome strain. On the other hand, transfecting a
trypanosome strain with a luminescence reporter gene
makes it possible to first select trypanocidal compounds
in vitro and subsequently test their activity in vivo with
the same trypanosome strain by bioluminescence imaging
of infected mice. Here we confirm that even after
transfection with pHD 309 RLuc, the in vitro and
in vivo growth characteristics of the recombinant T.b.
gambiense strain are not different from the wild type
strain. We used several drugs that are in use against T.b.
gambiense sleeping sickness to investigate whether the
pHD 309 RLuc integration would have altered the drug
sensitivity profile compared to the wild type. No such
influence could be observed. Furthermore, the IC50
values for these drugs fall within range of other T.b.
gambiense field strains isolated in Mbuji-Mayi, Demo-
cratic Republic of the Congo, that have been used re-
cently for validation of fexinidazole [20,26]. Before
the present LMVA can be adopted as HTS assay, fur-
ther evaluation and optimisation is necessary. Also,
the assay should be tested for its applicability on
other RLuc transfected Trypanozoon strains that have
become available recently, including T.b. brucei, T.b.
rhodesiense and T. evansi strains.Conclusions
In conclusion, we showed that a luminescent multiplex
viability assay with an RLuc transfected T.b. gambiense
strain can be used as an alternative to the resazurin via-
bility assay in drug discovery. Both the LMVA assay and
the trypanosome strain represent valuable assets in the
fight against sleeping sickness, complementing the avail-
able tools for HTS compound screening, particularly
where it comes to confirm in vivo trypanocidal activity
of molecules that have been selected in vitro.
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